Servier – Talk Bio

Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal

1 month ago talkbio0Tagged BDTX-4933, Black Populations, Diamond Therapeutics, licensing agreement, RAS/RAF inhibitor, Servier, Solid Neoplasm

Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor

Servier and Google Cloud Extend Partnership to Accelerate AI-Powered Drug Development

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, digital transformation, Drug Development, generative, Google Cloud, Pharmaceutical Research, R&D, Servier, therapeutic solutions

Servier, Google Cloud, AI, drug development, pharmaceutical research, digital transformation, R&D, generative AI, gen AI, therapeutic solutions.

FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios

9 months ago talkbio0Tagged Agios, Approved, Blood - brain barrier anatomy, Brain Neoplasms, cancer metabolism, IDH1 gene, IDH2 gene, Mutation, payment, Royalty, Servier, United States Food and Drug Administration, Voranigo

FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments